a Phase 2 trial for MTX-474 in systemic sclerosis
Latest Information Update: 16 Jan 2025
Price :
$35 *
At a glance
- Drugs MTX-474 (Primary)
- Indications Systemic scleroderma
- Focus Therapeutic Use
- 16 Jan 2025 New trial record
- 10 Jan 2025 Mediar Therapeutics anticipates to initiate this Phase 2 trial for MTX-474 in systemic sclerosis in the second half of 2025.